Tonix reports positive results from Phase ll trial of TNX-102 SL to treat PTSD

Tonix Pharmaceuticals has reported positive results from a Phase ll, dose-finding clinical trial of TNX-102 SL (cyclobenzaprine HCl sublingual tablets) to treat military-related post-traumatic stress disorder (PTSD).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news